Friday, 15 Dec 2017

Biologic/Novel Rx

Datesort ascending Type Title Save
13 Dec 2017 News FDA Approves Mepolizumab for Churg-Strauss (EGPA)
07 Dec 2017 Social Prospective study of 133 IBD pts (64% CD, 36% UC) switched from Remicade to biosimilar Inflectra. After 12 mos. no differences in drug levels, disease activity between innovator and biosimilar. https://t.co/QEH3lUaXD4
06 Dec 2017 News Do JAK Inhibitors Increase the Risk of Venous Thromboembolic Events?
05 Dec 2017 Social FDA listing of currently approved BIOSIMILARS and their product info. 5 of 8 are for rheumatology, think you know them? https://t.co/5dQ0PI9klE
22 Nov 2017 Social FDA approved rheumatology drugs in 2017: Brodalumab (Siliq); oral Methotrexate solution (Xatmep): Abaloparatide (Ty… https://t.co/uksc5fDYin
19 Nov 2017 Social This is the single best source on Biologics for Patients - Download the Patient Guide to Biologics from RheumNow. 6… https://t.co/JHClYEgixk
16 Nov 2017 Social RT @VickiShanmugam: Biologic therapy is associated with decline in disease activity in #Hidradenitis suppurativa with greatest impact seen…
15 Nov 2017 Social Abbvies 9/17 settlement with Amgen that allows Amgens adalimumab biosimilar (Amjevita) to begin sales in EU Oct 20… https://t.co/S21dfEjadJ
13 Nov 2017 Social This is the single best source on Biologics for Patients - Download the Patient Guide to Biologics from RheumNow. 6… https://t.co/m7LtJVAnfQ
08 Nov 2017 Social RT @Janetbirdope: No difference in lung safety of Abatacept and TNFI and one study of more ILD with IFX vs ABA #137. #acr17 @rheumnow #526…
08 Nov 2017 Social RT @Janetbirdope: #GAMECHANGER. Switching to a biosimilar in British registry shows no attenuation. #acr17 @rheumnow #2439 https://t.co/w4q…
07 Nov 2017 Social RT @Janetbirdope: #GAMECHANGER. If not responding to tociluzimab in RA you can respond to switch to 200 mg sarilab #acr17 @rheumnow #2468 h…
07 Nov 2017 Social RT @philipcrobinson: New Jak-1 selective inhibitor ABT-494 doesn’t look too bad #ACR17 @RheumNow https://t.co/sAHVqJr31a
07 Nov 2017 Social RT @KDAO2011: Plenary #2754 tailored RTX based on +ANCA +CD19 B cells performed as well as scheduled RTX for AAV #ACR17 @rheumnow
07 Nov 2017 Social RT @DrPetryna: #16L #acr17 no risk of DVTorPE w/Tofa from RTC trials analysis. IRs comparable to #corona data for Tofa&cDMARDs @RheumNow ht…
07 Nov 2017 Social RT @CCalabreseDO: Effect of live HZ vaccine in MTX-IR w/RA getting tofa or ADA +/- MTX: well-tolerated, higher HZ rates in tofa+MTX #2393 #…
07 Nov 2017 Social RT @japaoli19: Benefits of IL6 blockade on insulin resistance in RA #1400 #ACR17 @RheumNow https://t.co/tYFYRnRlof
07 Nov 2017 Social RT @CCalabreseDO: R. Fleischmann regarding biosimilars, “there are not savings for the patient” @RheumNow #ACR17 https://t.co/qdwVqsV3Zq
06 Nov 2017 Social RT @regeneron: In rheumatoid #arthritis, chronically elevated IL-6 levels may drive inflammation & joint destruction. #ACR17 https://t.co/h…
06 Nov 2017 Social RT @_connectedcare: Here’s a list of other biologics being trialed in GCA. An exciting time #acr17 @RheumNow https://t.co/nqNtRHSSni